Mustang BIO, Inc. (MBIO) intrinsic value & 10-year financials
Mustang BIO, Inc. (MBIO) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.38
- Market cap
- $1.8M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- 137.9%
- Free cash flow (FY2025)
- —
MBIO 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$1.9M | -$0.39 | — | — | 27.0% |
| FY2024 | — | -$15.8M | -$4.82 | -$11.4M | — | 218.4% |
| FY2023 | — | -$51.6M | -$0.75 | -$49.5M | — | 341.9% |
| FY2022 | — | -$77.5M | -$0.09 | -$67.8M | — | 718.4% |
| FY2021 | — | -$66.4M | -$0.10 | -$57.7M | — | -1883.4% |
| FY2020 | — | -$60.0M | — | -$39.2M | — | 2936.9% |
| FY2019 | — | -$46.4M | — | -$35.9M | — | -699.7% |
| FY2018 | — | -$30.7M | — | -$26.1M | — | -153.9% |
| FY2017 | — | -$31.3M | — | -$13.4M | — | -74.4% |
| FY2016 | — | -$12.7M | — | — | — | -52.1% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
MUSTANG BIO, INC. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
MUSTANG BIO, INC. has historically struggled to out-earn its cost of capital, averaging just -8.5% ROIC.
MUSTANG BIO, INC. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
MUSTANG BIO, INC. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.